Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Francque

Showing results (101-110 of 177) with videos related to

Pageof 18
Sort By:
European Journal of Gastroenterology & Hepatology|July 16, 2010
Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patientsRéginald Brenard, Xavier Chapaux, Pierre Deltenre, et al.
Hepatology International|September 9, 2022
Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver diseaseYuanyuan Kong, Tingting Lv, Min Li, et al.
Journal of Hepatology|February 24, 2015
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitisSven Francque, An Verrijken, Sandrine Caron, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 15, 2012
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architectureSven Francque, Wim Laleman, Len Verbeke, et al.
Journal of Hepatology|January 18, 2011
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patientsEsther Zimmermann, Rodolphe Anty, Joan Tordjman, et al.
The Journal of Clinical Endocrinology and Metabolism|September 23, 2017
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese SubjectsVanessa Legry, Sven Francque, Joel T Haas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 29, 2011
N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosisBram Blomme, Sven Francque, Eric Trépo, et al.
The American Journal of Gastroenterology|October 12, 2016
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD FibrosisStuart McPherson, Tim Hardy, Jean-Francois Dufour, et al.
Atherosclerosis|September 28, 2018
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk populationMatthieu Wargny, Pierre-Henri Ducluzeau, Jean-Michel Petit, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Pageof 18

Showing results (101-110 of 177) with videos related to

Sort By:
Pageof 18
European Journal of Gastroenterology & Hepatology|July 16, 2010
Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patientsRéginald Brenard, Xavier Chapaux, Pierre Deltenre, et al.
Hepatology International|September 9, 2022
Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver diseaseYuanyuan Kong, Tingting Lv, Min Li, et al.
Journal of Hepatology|February 24, 2015
PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitisSven Francque, An Verrijken, Sandrine Caron, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 15, 2012
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architectureSven Francque, Wim Laleman, Len Verbeke, et al.
Journal of Hepatology|January 18, 2011
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patientsEsther Zimmermann, Rodolphe Anty, Joan Tordjman, et al.
The Journal of Clinical Endocrinology and Metabolism|September 23, 2017
Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese SubjectsVanessa Legry, Sven Francque, Joel T Haas, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 29, 2011
N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosisBram Blomme, Sven Francque, Eric Trépo, et al.
The American Journal of Gastroenterology|October 12, 2016
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD FibrosisStuart McPherson, Tim Hardy, Jean-Francois Dufour, et al.
Atherosclerosis|September 28, 2018
Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk populationMatthieu Wargny, Pierre-Henri Ducluzeau, Jean-Michel Petit, et al.
Gastroenterology|February 14, 2016
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A Harrison, Sven Francque, et al.
Pageof 18